Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PORCN | Q9H237 | 10/20 | 0.55 |
| ▸ | WNT3A | P56704 | 8/20 | 0.55 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17675335 | 1.00 | PORCN (0.55) | PORCNWNT3APTK2 | |
| SCHEMBL22989737 | 0.84 | PORCN (0.54) | PORCNWNT3A | |
| SCHEMBL17675613 | 0.84 | WNT3A (0.61) | PORCNWNT3A | |
| SCHEMBL3712178 | 0.83 | KMT2A (0.59) | WNT3A | |
| SCHEMBL17673081 | 0.81 | PORCN (0.60) | PORCNWNT3A | |
| SCHEMBL17675369 | 0.80 | PORCN (0.47) | PORCNWNT3A | |
| SCHEMBL17316889 | 0.79 | ABL1 (0.54) | PTK2 | |
| SCHEMBL22975368 | 0.78 | PTK2 (0.56) | WNT3APTK2 | |
| SCHEMBL22975369 | 0.78 | PTK2 (0.56) | PTK2 | |
| SCHEMBL4237518 | 0.76 | RAB9A (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630633-B2 | Antibody molecules to PD-1 and uses thereof | NOVARTIS AG (CH) | 2026-05-19 | — | — | US | disclosed |
| CN-117752784-A | Dosing regimen of a combination of a Wnt inhibitor and an anti-PD-1 antibody molecule | 诺华股份有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-11827704-B2 | Antibody molecules to PD-1 and uses thereof | NOVARTIS AG (CH) | 2023-11-28 | — | — | US | disclosed |
| US-20230201194-A1 | COMBINATION COMPOSITIONS FOR IMMUNOTHERAPY | CUREGENIX CORPORATION | 2023-06-29 | — | — | US | disclosed |
| US-20230063366-A1 | Dosing schedule of a Wnt inhibitor and an anti-PD-1 antibody molecule in combination | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| JP-2022174157-A | DOSING SCHEDULE OF WNT INHIBITOR AND ANTI-PD-1 ANTIBODY MOLECULE IN COMBINATION | ノバルティス アーゲー | 2022-11-22 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827704-B2 | Antibody molecules to PD-1 and uses thereof | CD274, PDCD1, PDCD1LG2 | PORCN 4629/4885WNT3A 3491/4885PTK2 729/4885 |
| US-20230063366-A1 | Dosing schedule of a Wnt inhibitor and an anti-PD-1 antibody molecule in combination | WNT1, PDCD1, CTNNB1 | PORCN 3309/4885WNT3A 4/4885PTK2 806/4885 |
| US-12630633-B2 | Antibody molecules to PD-1 and uses thereof | CD40, CD274, ICOS | PORCN 4625/4885WNT3A 1366/4885PTK2 732/4885 |
| US-20230201194-A1 | COMBINATION COMPOSITIONS FOR IMMUNOTHERAPY | WNT1, CTNNB1, WNT3 | PORCN 3182/4885WNT3A 4/4885PTK2 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.